A trade group representing generic drugmakers is seeking an injunction to thwart a provision of a new Connecticut law that places a price cap on lower-cost copycat medicines, arguing the effort is “unconstitutional overreach.”
The law, which goes into effect in January, prohibits drugmakers from raising the prices of their medicines above the inflation rate. However, medicines sold by brand-name manufacturers are exempt until two years after those products lose patent protection, which means the focus is squarely on generic companies.
“We’ve seen drug prices, in general, as one of the very fastest-growing elements of state spending,” said Matt Lessler (D), the state Senate co-chair of the human services committee, who co-sponsored the legislation. “It seems clear that drug prices are growing across the board and putting pressure on the economy and health care affordability.”
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply